An observational study in Grass Pollen Allergy, sponsored by Allergy Therapeutics. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Allergy Therapeutics · Observational
Objective of this non-interventional study (NIS) is to collect data on the use of Grassmuno® in routine clinical practice.
1,055 studies on the registry are indexed under Hypersensitivity; 149 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 166 across 327 observational studies indexed under Hypersensitivity.
Browse Hypersensitivity studies →Allergy Therapeutics is the lead sponsor of 27 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult patients for whom a pre-seasonal subcutaneous allergen immunotherapy (AIT) with Grassmuno® for the treatment of IgE-mediated moderate to severe allergic rhinitis and/or rhinoconjunctivitis, without asthma or with well-controlled asthma elicicited by grass pollen is indicated.
At the physician's discretion and based on the current Summary of Product Characteristics (SmPC), study participation may be offered to patients who
Exclusion Criteria:
At the physician's discretion, the study should not be offered to the following patients:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients aged ≥ 18 for whom pre-seasonal subcutaneous allergen immunotherapy (AIT) with Grassmuno ® is indicated for the treatment of IgE-mediated moderate to severe allergic rhinitis and/or rhinoconjunctivitis with no asthma or with well-controlled asthma elicited by grass pollen allergy
Drug: Grassmuno®
SCIT for grass pollen allergy, observational study
Treatment adherence
Absolute number and percentage of treatment adherent patients after the first treatment year
Time frame: once a year for one year
Injection intervals
Analysis of dosing and injection intervals of Grassmuno®
Time frame: ~6 injection visits (visit 1 to visit 6) per treatment year
Treatment adherence
Absolute number an percentage of treatment adherent patients after the second treatment year and for first and second treatment year (total).
Time frame: once for a year for 2 years
Combined symptom and medication score (CSMS)
Combined symptom and medication score (CSMS) after the first and second year of treatment
Time frame: once a year for 2 years
Medications Score (dMS)
Medication scores (dMS) after the first and second year of treatment
Time frame: once a year for 2 years
Symptom Score (dSS)
Symptom score (dSS) after the first and second year of treatment
Time frame: once a year for two years
Rhinitis Quality of Life
Change in quality of life as assessed by the standardized Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ\[s\])
Time frame: three times a year (fist year), twice for 2nd year
Rhinitis and Rhinoconjunctivitis Score
Change from baseline in retrospectively collected data on rhinitis-, conjunctivitis-, and asthma-related symptoms (severity and frequency)
Time frame: once in two years
Patient Satisfaction
Absolute numbers and percentage of patients with a satisfaction grade (likert scale (very satisfied, satisfied, less satisfied, not satisfied), measured after the first and second year of treatment
Time frame: once a year for two years
Physican Satisfaction
Absolute numbers and percentage of physicians with a satisfaction grade (likert scale (very satisfied, satisfied, less satisfied, not satisfied), measured after the first and second year of treatment
Time frame: once a year for two years
Incidence of Treatment-emergent adverse events (safety and tolerability)
Type, frequency, and severity of adverse drug reactions (ADRs) occurring in association with treatment including frequency of ADRs leading to premature discontinuation of therapy
Time frame: all year for two years
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Oct 2028, 30 months after the start.
Of 124 observational studies under Hypersensitivity, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 136. This study's planned 30 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.